The study was led by a team of researchers in the Netherlands and involved 2,239 patients treated at two tertiary medical centers in Amsterdam between Dec. 31, 2018 and Jan. 6, 2021. Researchers found hospitalized patients taking the proton pump inhibitors had a nearly 50 percent higher chance of colonization of extended-spectrum beta-lactamase- or carbapenemase-producing Enterobacterales. The risk was slightly higher for hospitalized patients who took proton pump inhibitors twice a day.
While colonization doesn’t always lead to illness, it increases the risk of infection.
“These findings emphasize the judicious use of PPIs,” researchers said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.